Please login to the form below

Not currently logged in
Email:
Password:

Imdur

This page shows the latest Imdur news and features for those working in and with pharma, biotech and healthcare.

AZ adds gout drug Zurampic to asset sale

AZ adds gout drug Zurampic to asset sale

Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

Latest news

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    AZ offloads more products in slimming drive. Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline. ... Meanwhile, earlier this week AZ also transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    First launched in Europe in 1985, Imdur (isosorbide mononitrate) is an anti-angina drug in an oral extended release formulation with global sales outside the US of $57m in 2015. ... licence. 310. AstraZeneca/ CMS| Tibet Rhodiola Pharmaceutical Holding.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics